Skip to content
← Full study record

NCT01125293 · MORE INFO

Limitations, agreements, and source contact

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia · Source last updated 2021-04-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
point Of Contact
email
irene_ghobrial@dfci.harvard.edu
organization
Dana-Farber Cancer Institute
phone
617-632-4101
title
Irene Ghobrial
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
point Of Contact
email
irene_ghobrial@dfci.harvard.edu
organization
Dana-Farber Cancer Institute
phone
617-632-4101
title
Irene Ghobrial

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice